Acadian Asset Management
MCRB icon

Acadian Asset Management’s Seres Therapeutics MCRB Stock Holding History

Acadian Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,041
Closed -$141K – 1701
2023
Q4 		$141K Buy
+5,041
New +$132K ﹤0.01% 1299
2022
Q3 		– Sell
-6,589
Closed -$452K – 1773
2022
Q2 		$452K Buy
+6,589
New +$568K ﹤0.01% 1008
2020
Q1 		– Sell
-222
Closed -$16K – 1870
2019
Q4 		$16K Sell
222
-414
-65% -$30.7K ﹤0.01% 1735
2019
Q3 		$51K Buy
+636
New +$42K ﹤0.01% 1614
2017
Q2 		– Sell
-133
Closed -$30K – 1522
2017
Q1 		$30K Buy
+133
New +$27K ﹤0.01% 1315

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Acadian Asset Management's MCRB Position: Q1 2024 in Review

Acadian Asset Management sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 5,041 shares — an estimated $141K sold.

Acadian Asset Management first reported a position in MCRB in Q1 2017 and held it in 5 quarters. The position peaked at $452K in Q2 2022. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.

  • Acadian Asset Management reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Acadian Asset Management sold 5,041 Seres Therapeutics shares in Q1 2024, an estimated $141K.
  • Acadian Asset Management first reported a position in Seres Therapeutics in Q1 2017 and held it in 5 quarters.
  • Acadian Asset Management's Seres Therapeutics position peaked at $452K in Q2 2022.
  • 99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.

Based on Acadian Asset Management's 13F filing for Q1 2024, filed 10 May 2024.